Normal view MARC view ISBD view

What's new in molecular genetic pathology 2022: immune checkpoint inhibitor biomarkers and select solid tumors.

MedStar author(s):

Citation: Journal of Pathology & Translational Medicine. 56(2):113-114, 2022 Mar.PMID: 35306778Institution: MedStar Washington Hospital CenterDepartment: Pathology and Laboratory MedicineForm of publication: Journal ArticleMedline article type(s): Journal ArticleSubject headings: IN PROCESS -- NOT YET INDEXEDYear: 2022 ISSN:

2383-7837

Name of journal: Journal of pathology and translational medicineAbstract: Predictive biomarker testing plays a critical role in targeted immuno-oncology, including the use of immune checkpoint inhibitors (ICI) for various solid tumors. Molecular advancements in cancers of the breast, kidney and brain have continued to propel tumor classification and precision therapy.All authors: Chen G, Tsang PCFiscal year: FY2022 Digital Object Identifier:

https://dx.doi.org/10.4132/jptm.2022.01.25

Date added to catalog: 2022-05-11

Holdings ( 1 )
Title notes ( 2 )

Holdings
Item type	Current library	Collection	Call number	Status	Date due	Barcode
Journal Article	MedStar Authors Catalog	Article	35306778	Available		35306778

Predictive biomarker testing plays a critical role in targeted immuno-oncology, including the use of immune checkpoint inhibitors (ICI) for various solid tumors. Molecular advancements in cancers of the breast, kidney and brain have continued to propel tumor classification and precision therapy.

English